Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

QVT Financial

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 25
Average round size
info
The average size of a deal this fund participated in
$56M
Portfolio companies 20
Rounds per year 1.19
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.20
Exits 14
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Biopharma
  • Therapeutics
  • Medical
Summary

QVT Financial appeared to be the VC, which was created in 2003. The venture was found in North America in United States. The main department of described VC is located in the New York.

The standard case for the fund is to invest in rounds with 7-8 partakers. Despite the QVT Financial, startups are often financed by Sofinnova Partners, Gimv, Auriga Partners. The meaningful sponsors for the fund in investment in the same round are Venrock, Three Arch Partners, Foresite Capital. In the next rounds fund is usually obtained by Flagship Pioneering, Viking Global Investors, Three Arch Partners.

We also calculated 3 valuable employees in our database.

The average startup value when the investment from QVT Financial is more than 1 billion dollars. The high activity for fund was in 2014. The higher amount of exits for fund were in 2015. The usual things for fund are deals in the range of 50 - 100 millions dollars. The real fund results show that this VC is 14 percentage points less often commits exit comparing to other companies. Opposing the other organizations, this QVT Financial works on 40 percentage points more the average amount of lead investments. The fund is constantly included in less than 2 investment rounds annually.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight AveXis, Roivant Sciences, Adaptimmune. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Among the most popular fund investment industries, there are Broadcasting, Content.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of QVT Financial:
Typical Co-investors
QVT Financial is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after QVT Financial:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Clal Electronics Industries -
Feiteng Chuangtou China, Guangdong, Shenzhen
First Albany Companies Albany, New York, United States
GKM California, Los Angeles, United States
Mistral Equity Partners New York, New York, United States
Northwest Venture Associates Spokane, United States, Washington
RoseRock Bryan, Texas, United States
ZOLL Medical Corporation Chelmsford, Massachusetts, United States
Zuo'An Capital -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Active Surfaces

Renewable Energy
Solar
$5M13 May 2024 Salem, Massachusetts, United States

Kriya Therapeutics

Biotechnology
Life Science
$270M16 May 2022 Palo Alto, California, United States

Tourmaline Bio

Biotechnology
Clinical Trials
Therapeutics
01 May 2022 New York, New York, United States

Kriya Therapeutics

Biotechnology
Life Science
$100M14 Jul 2021 Palo Alto, California, United States

MP Materials

Industrial
Mining
Sustainability
01 Dec 2020 Las Vegas, Nevada, United States

Kriya Therapeutics

Biotechnology
Life Science
$80M12 May 2020 Palo Alto, California, United States

Adaptimmune

Biopharma
Biotechnology
Health Care
Medical
$104M25 Sep 2014 United Kingdom, England, United Kingdom

Concert Pharmaceuticals

Biotechnology
Health Care
Medical
$37M30 Apr 2008 Massachusetts, United States

Resolvyx Pharmaceuticals

Biotechnology
Pharmaceutical
Therapeutics
$25M22 Apr 2008 Cambridge, Massachusetts, United States
News
Kriya Therapeutics Completes $100 Million Series B Financing to Advance Its Fully Integrated Platform for Designing, Developing and Manufacturing Transformative Gene Therapies

– Kriya closed a $100m Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies.
– The financing was led by Patient Square Capital with participation from new investors Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures and others.
– All existing institutional investors also participated in this round, including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and JDRF T1D Fund.
– Proceeds from the financing will be used to further develop Kriya’s core technology platforms, expand its therapeutic pipeline and advance its current programs in metabolic disease, ophthalmology and oncology.
– Jim Momtazee, Managing Partner of Patient Square Capital, will join Kriya’s Board of Directors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent QVT Financial?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 25
Average round size 56M
Rounds per year 1.19
Peak activity year 2006
Lead investments 3
Follow on index 0.20
Exits 14
Group Appearance index 0.92

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Active Surfaces

Renewable Energy
Solar
$5M13 May 2024 Salem, Massachusetts, United States

Kriya Therapeutics

Biotechnology
Life Science
$270M16 May 2022 Palo Alto, California, United States

Tourmaline Bio

Biotechnology
Clinical Trials
Therapeutics
01 May 2022 New York, New York, United States

Kriya Therapeutics

Biotechnology
Life Science
$100M14 Jul 2021 Palo Alto, California, United States

MP Materials

Industrial
Mining
Sustainability
01 Dec 2020 Las Vegas, Nevada, United States

Kriya Therapeutics

Biotechnology
Life Science
$80M12 May 2020 Palo Alto, California, United States

Adaptimmune

Biopharma
Biotechnology
Health Care
Medical
$104M25 Sep 2014 United Kingdom, England, United Kingdom

Concert Pharmaceuticals

Biotechnology
Health Care
Medical
$37M30 Apr 2008 Massachusetts, United States

Resolvyx Pharmaceuticals

Biotechnology
Pharmaceutical
Therapeutics
$25M22 Apr 2008 Cambridge, Massachusetts, United States
Crunchbase icon

Content report

The following text will be sent to our editors: